Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
AK

NASDAQ · AKTS

Aktis Oncology, Inc.

Healthcare · Biotechnology

$22.71

Up+$0.30 (+1.34%)

Updated Sep 17, 2026, 3:22 AM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.06B
P/E ratio
0
Dividend yield
0.00%
52-week range
$0.03 – $34.19
Volume
855.05K
Avg. volume
374.39K

Price performance

AKTS price history

1M range · 20 trading sessions · Daily adjusted prices

AKTS closed at $22.71 after 20 trading sessions, down 9.23% for the selected period.

Last close
$22.71
Period change
-9.23%
Period low
$22.41
Period high
$27.05
Daily close
View OHLC price history
AKTS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$22.48$22.9428$21.31$22.71855.05K
Sep 15, 2026$23.21$23.21$22.18$22.41290.43K
Sep 14, 2026$23.36$23.705$22.79$23.17330.08K
Sep 11, 2026$24.36$24.54$23.25$23.30228.58K
Sep 10, 2026$23.80$24.355$23.57$23.94263.62K
Sep 9, 2026$25.57$26.00$24.03$24.06377.36K
Sep 8, 2026$26.99$26.99$24.23$25.02567.43K
Sep 4, 2026$26.18$27.20$26.18$27.05159.25K
Sep 3, 2026$27.29$27.6633$26.08$26.65152.78K
Sep 2, 2026$26.12$27.03$25.705$26.92253.45K
Sep 1, 2026$25.80$26.2025$25.1243$25.99231.52K
Aug 31, 2026$25.57$26.05$25.14$25.91213.62K
Aug 28, 2026$25.96$26.80$25.52$25.78314.65K
Aug 27, 2026$26.32$27.175$26.15$26.18210.63K
Aug 26, 2026$26.60$26.96$25.96$26.51257.59K
Aug 25, 2026$26.30$26.89$25.4736$26.69601.24K
Aug 24, 2026$24.15$26.3055$22.955$25.98774.58K
Aug 21, 2026$24.33$25.00$24.00$24.07226.36K
Aug 20, 2026$24.75$24.75$23.4374$24.00253.62K
Aug 19, 2026$26.28$26.28$24.42$25.02216.57K

Latest AKTS news

The latest Smart Investors Daily articles mentioning AKTS.

Stock researchCompany · Overview

AKTS research

Overview

Company profile and research snapshot.

Company profile

Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.92
Implied upside
—
Analysts
—
AKTS recent ratings
DateFirmRatingTarget
Sep 9, 2026OppenheimerOutperform—
Aug 19, 2026WedbushOutperform—
Aug 19, 2026BMO CapitalOutperform—
Jul 14, 2026JP MorganOverweight—
Jun 16, 2026Raymond JamesStrong Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Aktis Oncology to Present at Upcoming September Investor Conferences

BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will participate in the following investor conferences in September. Morgan Stanley 24th Annual Global Healthcare C

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By